All In Biotech

Investigational drug · Phase 2

REGN5381

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

5

Any phase or sponsor naming "REGN5381"

First trial start

2022

Jun 30, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "REGN5381", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Heart Failure

Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "REGN5381" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Heart Failure

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • VicadrostatBI 690517Phase 35 trials

    Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension

  • IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials

    Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy

  • ZiltivekimabPhase 34 trials

    Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure

  • HiCM-188 therapyPhase 32 trials

    HELP Therapeutics Co., Ltd. · Heart Failure

  • Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction

  • IMR-687Tovinontrine, CRD-750Phase 23 trials

    Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases

  • CDR132LPhase 22 trials

    Novo Nordisk · Heart Failure

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.